Huateng Pharmaceutical, a global supplier of pharmaceutical Intermediates, offers Irbesartan Intermediates Triphenyl irbesartan (CAS NO. 138402-10-5) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.
Application: It is a useful building block, especially in the preparation of the antihypertensive drug, irbesartan.
*The following content is generated by AI and is for reference only.
Triphenyl irbesartan is not a recognized or commercially available pharmaceutical compound. Irbesartan (CAS No. 138402-11-6) is a well-established angiotensin II receptor blocker (ARB) used clinically to treat hypertension and diabetic nephropathy, with the molecular formula C25H28N6O. The term "triphenyl" likely stems from a misunderstanding, as irbesartan does not contain a triphenyl moiety in its standard structure; it features an imidazole ring substituted with a biphenyl tetrazole group and a cyclohexane carboxylic acid derivative. There are no verified records of a "triphenyl irbesartan" variant in scientific databases such as PubChem, ChemSpider, or regulatory filings by the FDA or EMA.
The confusion may arise from structural analogs or synthetic intermediates studied in medicinal chemistry research, where triphenyl groups sometimes appear in related ARB derivatives for pharmacokinetic optimization. However, no such compound has progressed to clinical use or commercial production. Standard irbesartan functions by selectively blocking the AT1 receptor, preventing vasoconstriction and aldosterone release, thereby lowering blood pressure without affecting heart rate significantly. It is typically administered orally once daily, with high bioavailability and minimal drug-drug interactions.
If you encountered "triphenyl irbesartan" in a non-peer-reviewed source, it may refer to a mislabeled substance, a hypothetical molecule, or an error in nomenclature. Researchers should verify chemical identities using authoritative databases before proceeding with synthesis or application. For legitimate therapeutic needs, approved irbesartan formulations remain the gold standard. Always consult healthcare professionals and rely on validated scientific literature when dealing with pharmaceutical compounds to ensure safety and efficacy. Misidentification of chemical structures can lead to serious health risks or experimental failures.